Precigen vs Suzhou Zelgen Biopharmaceuticals: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Precigen Inc (PGEN)

Q3 202615 Jul – 5 Oct 2026

▲3▼1

Papzimeos Sales Boom and FDA Platform Win Drive PGEN Higher

Q2 earnings blow past estimates Precigen reported Q2 2026 GAAP EPS of $0.05, beating estimates by $0.06, and revenue of $54.98 million, beating forecasts by $27.15 million. This is the first clear proof the company can sell its drug at scale, which supports a higher stock price.
The earnings beat is the fundamental catalyst that validates the commercial launch and re-rates the stock.
Papzimeos sales more than double sequentially Papzimeos, the only approved therapy for recurrent respiratory papillomatosis, brought in $74.6 million in the first half of 2026, with Q2 sales more than doubling from Q1. Management says demand kept growing into Q3, showing the launch is still accelerating.
This is the core revenue driver behind the stock's 52.5% three-month gain and the main reason investors are bullish.
FDA platform designation opens pipeline upside The FDA granted platform technology designation to Precigen's AdenoVerse platform, which underpins Papzimeos and the experimental PRGN-2009 for HPV-related cancers. This could speed up and de-risk future drug approvals, adding value beyond the current one marketed product.
The designation expands the long-term opportunity and is a fresh regulatory win that supports the bull case.
Valuation and competition are real risks PGEN trades at 32.4 times sales, far above the biotech group average of 12.1 times, so any disappointment could hit hard. Rival Inovio's competing RRP therapy faces an FDA decision on Oct. 30, 2026, which could challenge Papzimeos's market lead.
This is the main counterweight: a stretched valuation and a near-term competitive threat that could reverse gains.

August 202615 Jul – 5 Oct 2026

▲3▼1

Papzimeos Sales Boom and FDA Platform Win Drive PGEN Higher

Q2 earnings blow past estimates Precigen reported Q2 2026 GAAP EPS of $0.05, beating estimates by $0.06, and revenue of $54.98 million, beating forecasts by $27.15 million. This is the first clear proof the company can sell its drug at scale, which supports a higher stock price.
The earnings beat is the fundamental catalyst that validates the commercial launch and re-rates the stock.
Papzimeos sales more than double sequentially Papzimeos, the only approved therapy for recurrent respiratory papillomatosis, brought in $74.6 million in the first half of 2026, with Q2 sales more than doubling from Q1. Management says demand kept growing into Q3, showing the launch is still accelerating.
This is the core revenue driver behind the stock's 52.5% three-month gain and the main reason investors are bullish.
FDA platform designation opens pipeline upside The FDA granted platform technology designation to Precigen's AdenoVerse platform, which underpins Papzimeos and the experimental PRGN-2009 for HPV-related cancers. This could speed up and de-risk future drug approvals, adding value beyond the current one marketed product.
The designation expands the long-term opportunity and is a fresh regulatory win that supports the bull case.
Valuation and competition are real risks PGEN trades at 32.4 times sales, far above the biotech group average of 12.1 times, so any disappointment could hit hard. Rival Inovio's competing RRP therapy faces an FDA decision on Oct. 30, 2026, which could challenge Papzimeos's market lead.
This is the main counterweight: a stretched valuation and a near-term competitive threat that could reverse gains.

Latest15 Jul – 5 Oct 2026

▲3▼1

Papzimeos Sales Boom and FDA Platform Win Drive PGEN Higher

Q2 earnings blow past estimates Precigen reported Q2 2026 GAAP EPS of $0.05, beating estimates by $0.06, and revenue of $54.98 million, beating forecasts by $27.15 million. This is the first clear proof the company can sell its drug at scale, which supports a higher stock price.
The earnings beat is the fundamental catalyst that validates the commercial launch and re-rates the stock.
Papzimeos sales more than double sequentially Papzimeos, the only approved therapy for recurrent respiratory papillomatosis, brought in $74.6 million in the first half of 2026, with Q2 sales more than doubling from Q1. Management says demand kept growing into Q3, showing the launch is still accelerating.
This is the core revenue driver behind the stock's 52.5% three-month gain and the main reason investors are bullish.
FDA platform designation opens pipeline upside The FDA granted platform technology designation to Precigen's AdenoVerse platform, which underpins Papzimeos and the experimental PRGN-2009 for HPV-related cancers. This could speed up and de-risk future drug approvals, adding value beyond the current one marketed product.
The designation expands the long-term opportunity and is a fresh regulatory win that supports the bull case.
Valuation and competition are real risks PGEN trades at 32.4 times sales, far above the biotech group average of 12.1 times, so any disappointment could hit hard. Rival Inovio's competing RRP therapy faces an FDA decision on Oct. 30, 2026, which could challenge Papzimeos's market lead.
This is the main counterweight: a stretched valuation and a near-term competitive threat that could reverse gains.

Suzhou Zelgen Biopharmaceuticals Co Ltd (688266.CG)

Q3 202621 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.

August 202621 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.

Latest21 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.